Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
E3 ubiquitin-protein ligase RNF26 is a transmembrane enzyme of the endoplasmic reticulum (ER), characterized by a C3HC5-type RING finger domain and an N-terminal leucine zipper[3][4]. It plays a critical role in the spatial organization of endosomes and perinuclear ER integrity by retaining vesicles in the perinuclear “cloud,” and it mediates ubiquitination of substrates such as SQSTM1/p62 and MITA/STING[1][4][5]. RNF26 acts as a platform for positioning the endosomal system and is involved in antiviral innate immune responses by regulating type I interferon signaling through targeted polyubiquitination of MITA/STING and autophagic degradation of IRF3[5]. It also interacts with cytoskeletal protein vimentin to regulate organelle localization and ER morphology, especially under stress conditions[1]. RNF26 expression is upregulated in various human cancers, suggesting it may contribute to carcinogenesis through dysregulation of its ubiquitination targets[3][4].
Drugs or molecules targeting RNF26 would most likely act by inhibiting or modifying its E3 ligase activity, affecting the ubiquitination of substrates such as SQSTM1/p62 or MITA/STING[5][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on E3 ubiquitin-protein ligase RNF26 (RNF26).